Cardiologists need to embrace the wave of new drugs, say experts, particularly since they can reduce the risk of CVD.

In DETECT AS, the passive notifications improved rates of AVR and boosted survival, with bigger gains in women.

The once-monthly drug is still under study but could provide added convenience and another option for patients.

In an early look at SCOT-HEART 2, CCTA led more primary-prevention patients to make changes to reduce their risk of CVD.

Acute MI mortality has fallen, yet deaths from other diseases, including heart failure and hypertension, are on the rise.